Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Sabina Signoretti, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Sabina Signoretti and James Mier.
Sabina Signoretti
Connection Strength
1.024
James Mier
  1. Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2019 Jul 01; 25(13):4194.
    View in: PubMed
    Score: 0.211
  2. Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. J Clin Oncol. 2013 Feb 20; 31(6_suppl):370.
    View in: PubMed
    Score: 0.136
  3. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther. 2010 Oct; 9(10):2793-802.
    View in: PubMed
    Score: 0.114
  4. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res. 2010 Jul 15; 16(14):3628-38.
    View in: PubMed
    Score: 0.113
  5. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21.
    View in: PubMed
    Score: 0.079
  6. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017 May 01; 23(9):2159-2168.
    View in: PubMed
    Score: 0.044
  7. Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother. 2016 12; 65(12):1523-1532.
    View in: PubMed
    Score: 0.044
  8. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget. 2016 Jul 05; 7(27):41857-41869.
    View in: PubMed
    Score: 0.043
  9. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res. 2015 Apr 15; 21(8):1925-1934.
    View in: PubMed
    Score: 0.039
  10. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8.
    View in: PubMed
    Score: 0.038
  11. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer. 2013 Feb 05; 108(2):319-26.
    View in: PubMed
    Score: 0.034
  12. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Transl Med. 2011 Dec 21; 9:220.
    View in: PubMed
    Score: 0.031
  13. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One. 2011 Apr 29; 6(4):e19144.
    View in: PubMed
    Score: 0.030
  14. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51.
    View in: PubMed
    Score: 0.026
  15. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):758s-763s.
    View in: PubMed
    Score: 0.022
  16. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005 Apr 15; 65(8):3044-8.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.